S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
New CBOE “special perk” helps traders target income every weekend (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
New CBOE “special perk” helps traders target income every weekend (Ad)
2 energy drink makers to wake up your portfolio
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
New CBOE “special perk” helps traders target income every weekend (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
New CBOE “special perk” helps traders target income every weekend (Ad)
2 energy drink makers to wake up your portfolio
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
New CBOE “special perk” helps traders target income every weekend (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
New CBOE “special perk” helps traders target income every weekend (Ad)
2 energy drink makers to wake up your portfolio
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
New CBOE “special perk” helps traders target income every weekend (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
New CBOE “special perk” helps traders target income every weekend (Ad)
2 energy drink makers to wake up your portfolio
Snowflake’s bullish tailwind is turning into a gale-force wind

Sage Therapeutics Stock Price, News & Analysis (NASDAQ:SAGE)

$20.84
+0.45 (+2.21%)
(As of 12/4/2023 ET)
Compare
Today's Range
$19.81
$20.84
50-Day Range
$17.10
$21.31
52-Week Range
$16.51
$59.99
Volume
653,293 shs
Average Volume
943,657 shs
Market Capitalization
$1.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.78

Sage Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
110.1% Upside
$43.78 Price Target
Short Interest
Bearish
17.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.46
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($9.06) to ($6.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.49 out of 5 stars

Medical Sector

157th out of 952 stocks

Pharmaceutical Preparations Industry

61st out of 434 stocks


SAGE stock logo

About Sage Therapeutics Stock (NASDAQ:SAGE)

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid, which has completed Phase III clinical trials for treating PPD and major depressive disorders, as well as is in Phase II clinical trials for treatment resistant depression, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. Its product pipeline also comprises SAGE-689 that is in Phase II clinical trial for treating acute GABA hypofunction; SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

SAGE Stock Price History

SAGE Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
TD Cowen Keeps Their Hold Rating on Spero Therapeutics (SPRO)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Why Sage Therapeutics Stock Sank Today
Sage Therapeutics Q3 2023 Earnings Preview
Scotiabank Keeps Their Buy Rating on Biomea Fusion (BMEA)
See More Headlines
Receive SAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/15/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SAGE
Employees
689
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$43.78
High Stock Price Target
$294.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+110.1%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
18 Analysts

Profitability

Net Income
$-532,780,000.00
Net Margins
-5,779.62%
Pretax Margin
-5,779.62%

Debt

Sales & Book Value

Annual Sales
$7.69 million
Book Value
$21.05 per share

Miscellaneous

Free Float
56,790,000
Market Cap
$1.25 billion
Optionable
Optionable
Beta
1.11
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Barry E. GreeneMr. Barry E. Greene (Age 60)
    President, CEO & Director
    Comp: $1.29M
  • Ms. Kimi E. Iguchi CPA (Age 61)
    CFO & Treasurer
    Comp: $665.37k
  • Ms. Anne Marie Cook Esq. (Age 61)
    Senior VP, General Counsel & Secretary
    Comp: $711.6k
  • Mr. Christopher Benecchi (Age 51)
    Chief Business Officer
    Comp: $703.76k
  • Dr. Laura Gault M.D.
    Ph.D., Chief Medical Officer
  • Mr. Matt Lasmanis
    Chief Technology & Innovation Officer
  • Mr. Mike Quirk
    Chief Scientific Officer
  • Helen Rubinstein
    Investor Relations Officer
  • Ms. Erin E. Lanciani (Age 54)
    Chief People & Experience Officer
  • Dr. Amy Schacterle Ph.D.
    Senior Vice President of R&D Strategy and Business Management














SAGE Stock Analysis - Frequently Asked Questions

Should I buy or sell Sage Therapeutics stock right now?

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last twelve months. There are currently 15 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View SAGE analyst ratings
or view top-rated stocks.

What is Sage Therapeutics' stock price target for 2024?

18 brokers have issued twelve-month price targets for Sage Therapeutics' shares. Their SAGE share price targets range from $20.00 to $294.00. On average, they predict the company's share price to reach $43.78 in the next year. This suggests a possible upside of 110.1% from the stock's current price.
View analysts price targets for SAGE
or view top-rated stocks among Wall Street analysts.

How have SAGE shares performed in 2023?

Sage Therapeutics' stock was trading at $38.14 on January 1st, 2023. Since then, SAGE shares have decreased by 45.4% and is now trading at $20.84.
View the best growth stocks for 2023 here
.

When is Sage Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024.
View our SAGE earnings forecast
.

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) announced its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($2.81) EPS for the quarter, missing analysts' consensus estimates of ($2.64) by $0.17. The biopharmaceutical company earned $2.72 million during the quarter, compared to the consensus estimate of $9.02 million. Sage Therapeutics had a negative net margin of 5,779.62% and a negative trailing twelve-month return on equity of 59.46%.

What ETFs hold Sage Therapeutics' stock?
What other stocks do shareholders of Sage Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

Who are Sage Therapeutics' major shareholders?

Sage Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (12.83%), Wellington Management Group LLP (10.96%), RTW Investments LP (8.59%), JPMorgan Chase & Co. (2.78%), Deutsche Bank AG (1.72%) and Deutsche Bank AG (1.71%). Insiders that own company stock include Barry E Greene, Barry E Greene, Elizabeth Barrett, George Golumbeski, James M Frates and Jeffrey M Jonas.
View institutional ownership trends
.

How do I buy shares of Sage Therapeutics?

Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SAGE) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -